ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,427.13
      -2.31%
      US Tech 100
      18,601.20
      -3.24%
      Dow Jones
      39,853.87
      -1.25%
      Brent Oil
      80.735
      0.00%
      Bitcoin
      65,503.64
      0.20%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gossamer Bio Inc (GOSS) Quote

      Gossamer Bio Inc

      Gossamer Bio Inc (GOSS)

      NASDAQ
      1.06
      -0.01
      (-0.93%)
      Closed July 24 4:00PM
      Delayed by 15 minutes
      1.08
      0.02
      (1.89%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.08
      Bid
      1.08
      Ask
      1.09
      Volume
      803,909
      1.05 Day's Range 1.15
      0.4525 52 Week Range 1.60
      Market Cap
      244.316M
      Previous Close
      1.07
      Open
      1.06
      Last Trade
      1
      @
      1.09
      Last Trade Time
      Financial Volume
      $ 881,722
      VWAP
      1.0968
      Average Volume (3m)
      2,506,887
      Shares Outstanding
      226,218,652
      Dividend Yield
      -
      PE Ratio
      -1.33
      Earnings Per Share (EPS)
      -0.79
      Revenue
      -
      Net Profit
      -179.82M

      About Gossamer Bio Inc

      Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth,... Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.gossamerbio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Gossamer Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOSS. The last closing price for Gossamer Bio was $1.07. Over the last year, Gossamer Bio shares have traded in a share price range of $ 0.4525 to $ 1.60.

      Gossamer Bio currently has 226,218,652 shares outstanding. The market capitalization of Gossamer Bio is $242.05 million. Gossamer Bio has a price to earnings ratio (PE ratio) of -1.33.

      GOSS Latest News

      More News

      Form 8-K - Current report

      July 18 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 10 2024
      Edgar (US Regulatory)

      Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

      June 07 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      June 06 2024
      Edgar (US Regulatory)

      Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

      Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

      May 14 2024
      Business Wire

      Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

      May 10 2024
      Business Wire

      Form 8-K - Current report

      May 07 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 07 2024
      Edgar (US Regulatory)

      Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

      - Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD...

      May 07 2024
      Business Wire

      Form 8-K - Current report

      May 06 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.19-14.96062992131.271.27391.0211580911.06826456CS
      40.08468.499095840870.99541.370.862619630981.09434401CS
      120.3752.11267605630.711.370.499325068870.80422488CS
      260.21925.43554006970.8611.60.499318681440.92511181CS
      52-0.28-20.58823529411.361.60.452518789720.8997306CS
      156-6.29-85.34599728637.3715.1950.452519508593.42983178CS
      260-16.92-941827.14970.452514018325.04278187CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NUZENuZee Inc
      $ 3.2954
      (219.94%)
      		135.82M
      DRMADermata Therapeutics Inc
      $ 2.55
      (96.15%)
      		65.31M
      PIRSPieris Pharmaceuticals Inc
      $ 14.9491
      (87.33%)
      		5.85M
      SLNASelina Hospitality PLC
      $ 0.0456
      (75.38%)
      		1.22B
      QXOQXO Inc
      $ 119.99
      (51.31%)
      		218.2k
      NXTTNext Technology Holding Inc
      $ 2.50
      (-57.04%)
      		965.73k
      NUWENewellis Inc
      $ 2.48
      (-40.24%)
      		1.01M
      LITMSnow Lake Resources Ltd
      $ 0.625
      (-35.43%)
      		5.76M
      VWEVintage Wine Estates Inc
      $ 0.0732
      (-34.58%)
      		37.22M
      CONNConns Inc
      $ 0.345
      (-31.95%)
      		4.45M
      SLNASelina Hospitality PLC
      $ 0.0456
      (75.38%)
      		1.22B
      NVDANVIDIA Corporation
      $ 114.25
      (-6.80%)
      		327.86M
      SGMOSangamo Therapeutics Inc
      $ 0.5584
      (39.15%)
      		263.13M
      SQQQProShares UltraPro Short QQQ
      $ 9.06
      (10.76%)
      		203.95M
      TSLATesla Inc
      $ 215.99
      (-12.33%)
      		168.55M

      GOSS Discussion

      View Posts
      georgie18 georgie18 10 hours ago
      GOSS...$1.11...Reversal Candle setting up here...🥳...ready for another move ...Looking for Break/Hold of $1.38 and on to $1.60 Range...imo...we shall see...

      georgie18

      Member Level
      Re: georgie18 post# 381844

      Thursday, July 11, 2024 12:30:52 PM

      Post#
      381873
      of 382071
      GOSS...$1.31....HOD...Off the .66 range bottom...🥳
      👍️0
      Monksdream Monksdream 4 days ago
      GOSS under $2
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.31....HOD...Off the .66 range bottom...🥳
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.25...Off the .66 Range Bottom...🥳
      👍️0
      TechandBio TechandBio 2 weeks ago
      Gossamer Nice 178% move from where I got in regret not buying more a win is a win. Rivian and ICCM accumulating..
      $GOSS
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.20...Getting hits into the close...🥳
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.17...Trying Red to Green here...🥳
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.15...slowly creeping up off the .50 range bottom...🥳
      👍️0
      georgie18 georgie18 2 weeks ago
      GOSS...$1.10...Red to Green here...🥳Off the .50 range bottom...
      👍️0
      Monksdream Monksdream 3 weeks ago
      GOSS under $2
      👍️0
      georgie18 georgie18 3 weeks ago
      GOSS...$1.04... https://schrts.co/QnRKixhB ...🥳...Looking for the $1.09 Break and a move to $1.60 plus range...Off the .50 range bottom...
      👍️0
      georgie18 georgie18 4 weeks ago
      GOSS...9348...Trying red to green here off THE 200MA Bounce...🥳
      👍️0
      georgie18 georgie18 4 weeks ago
      GOSS...$1.02...on the 100/200MA Break...🥳...If this holds then we have a double top to break $1.60 range...
      👍️0
      georgie18 georgie18 4 weeks ago
      GOSS...939...🥳in the P/M...
      👍️0
      glenn1919 glenn1919 4 weeks ago
      GOSS................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
      👍️0
      georgie18 georgie18 1 month ago
      GOSS...86...Perhaps we see the Break/Hold of the 100MA at .93...🥳
      👍️0
      georgie18 georgie18 1 month ago
      GOSS...755...🥳...on the upper bollie Break...Break/Hold .87 and we have a runner...imo...we shall see...
      👍️0
      Pennyhero Pennyhero 1 month ago
      Ready for take off! 🚀🚀🚀
      👍️0
      georgie18 georgie18 1 month ago
      GOSS...71s clearing here...🥳
      👍️0
      georgie18 georgie18 1 month ago
      GOSS...673...Trying for the 50MA Breakout here...🥳
      👍️0
      georgie18 georgie18 1 month ago
      GOSS...66...on the Upper Bollie Break...🥳
      👍️0
      Termite7 Termite7 2 months ago
      Assuming phase 3 approval, what price? Thanks!!!
      👍️0
      FlippinNDippin FlippinNDippin 3 months ago
      Took a starter here. GLTA
      👍️0
      Monksdream Monksdream 4 months ago
      GOSS under $2
      👍️0
      glenn1919 glenn1919 4 months ago
      GOSS..........................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      GOSS..................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      GOSS......................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      GOSS under $2
      👍️0
      Monksdream Monksdream 10 months ago
      GOSS new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      GOSS new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      GOSS new 52 week low
      👍️0
      Dutch4 Dutch4 1 year ago
      Agreed!
      👍️0
      hippityhop hippityhop 2 years ago
      Institutionals shorting this unmercilessly. Three trades totalling 2.4M total shares bought at 4 pm. @ .20 cent profit a share come to $468k.
      👍️0
      hippityhop hippityhop 2 years ago
      This is a 100/200 percenter in next 3 months, buy this now or weep later!!
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
      7:13 am ET April 18, 2022 (Benzinga) Print
      Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.

      Latest Ratings for GOSS DateFirmActionFromTo

      Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Mar 2021HC Wainwright & Co.ReiteratesBuy
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
      👍️0

      Your Recent History

      NASDAQ
      GOSS
      Gossamer Bio
      FTSE
      E3X351020
      FTSEurofirst 300 Real Es...
      Delayed Upgrade Clock